Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.58 |
| ▸ | CTSK | P43235 | 17/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812341 | 0.89 | CTSS (0.60) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL3812344 | 0.89 | CTSS (0.60) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL29907919 | 0.89 | CTSS (0.60) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL17912348 | 0.89 | CTSS (0.60) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL29842925 | 0.89 | CTSS (0.60) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL25219488 | 0.82 | CTSS (0.50) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL5969521 | 0.79 | PTPN1 (0.51) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL844027 | 0.78 | CTSS (0.67) | CTSSCTSKCTSLCTSB | |
| SCHEMBL2684894 | 0.78 | CTSS (0.67) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5873422 | 0.78 | CTSS (0.67) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885CTSL 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.